Drug Trial Radar · NCT07565597
A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Actual
Start
May 12, 2026
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants
Conditions
- Healthy
Interventions
Gecacitinib Hydrochloride TabletsDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) Of Gecacitinib and its main metabolite ZG0244Time frame: up to 48 hours
- Gecacitinib and its main metabolite ZG0244 AUC(0-t)Time frame: up to 48 hours
- Gecacitinib and its main metabolite ZG0244 AUC(0-inf)Time frame: up to 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Hospital of Changsha
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.